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Serum acetate increases upon systemic infection. Acutely, assimilation of acetate expands 31 
the capacity of memory CD8+ T cells to produce IFN-. Whether acetate modulates memory 32 
CD8+ T cell metabolism and function during pathogen re-encounter remains unexplored. Here 33 
we show that at sites of infection high acetate concentrations are being reached, yet memory 34 
CD8+ T cells shut down the acetate assimilating enzymes ACSS1 and ACSS2. Acetate, being 35 
thus largely excluded from incorporation into cellular metabolic pathways, now had different 36 
effects, namely (i) directly activating glutaminase, thereby augmenting glutaminolysis, 37 
cellular respiration and survival, and (ii) suppressing TCR-triggered calcium-flux, and 38 
consequently cell activation and effector cell function. In vivo, high acetate abundance at sites 39 
of infection improved pathogen clearance while reducing immunopathology. This indicates 40 
that, during different stages of the immune response, the same metabolite – acetate – 41 
induces distinct immunometabolic programs within the same cell type.42 
 3 
Introduction 43 
Memory CD8+ T cells are a small population of long-lived immune cells with protective 44 
function and unique metabolic characteristics. Effector memory (EM) CD8+ T cells circulate 45 
between the blood and the periphery and migrate into various peripheral tissues, where they 46 
are exposed to constantly changing microenvironments. At tissue-sites, EM CD8+ T cells 47 
rapidly respond upon re-encounter of cognate antigen by producing pro-inflammatory 48 
cytokines and other effector molecules (Harty and Badovinac, 2008). During differentiation 49 
from naïve to effector to memory cells, CD8+ T cells undergo important metabolic changes, 50 
which have been intimately linked to their functional properties. 51 
Immune cells are able to respond to their environment and acquire a variety of context-52 
dependent fates. However, we are only beginning to understand how immune cells sense 53 
these environmental cues, and how this impacts immune cell metabolism and function. 54 
Previously we observed that systemic acetate levels rapidly increase upon infection in mice, 55 
and that, acutely, acetate at 'stress levels' enhances the glycolytic capacity and effector 56 
function of EM CD8+ T cells upon subsequent re-stimulation in low acetate abundance (Balmer 57 
et al., 2016). Mechanistically, in the acute scenario acetate is assimilated via acetyl-CoA 58 
synthetase 2 (ACSS2), and is expanding the cellular acetyl-CoA pool in an ATP-citrate lyase 59 
(ACLY) dependent manner, providing acetyl-groups for acetylation reactions. Acetylation of 60 
GAPDH increases its enzymatic activity, leading to increased glycolytic activity upon 61 
activation, and augmented EM CD8+ T cell effector function. Consistent with this finding, 62 
another report recently found an improved response to influenza infection in mice fed a high-63 
fiber diet. In this experimental system, diet-derived short-chain fatty acids (SCFAs), including 64 
acetate, enhanced cellular metabolism of CD8+ T cells, thereby boosting anti-viral activity 65 
(Trompette et al., 2018). 66 
To redirect immune cells to sites of infection, chemokine gradients are established and 67 
modulate lymphocyte trafficking (Kunkel and Butcher, 2002). Several metabolites also guide 68 
lymphocyte migration (Sigmundsdottir and Butcher, 2008), such as sphingosine-1-phosphate 69 
(Pappu et al., 2007), retinoic acid (Iwata et al., 2004; Svensson et al., 2008) or vitamin D3 70 
(Reiss et al., 2001). 71 
Metabolites, including acetate, may therefore be viewed as carrying information that can 72 
alter immune cell function. Whether, in extension of this concept, metabolites impact 73 
immune cell function according to the stage of an evolving immune response has not been 74 
explored. Here we extended our study of acetate acutely and transiently accumulating in the 75 
blood circulation to its role at sites of prolonged inflammation in murine and human memory 76 
CD8+ T cells.  77 
 4 
Results 78 
Acetate-levels are increased up to 100-fold at sites of infection and suppress ACSS1 and ACSS2 79 
expression in CD8+ T cells 80 
Acetate rapidly accumulates in the circulation upon systemic infection in mice (Balmer et al., 81 
2016). Several studies have shown dramatic changes in many metabolites in the setting of 82 
infection (Nguyen et al., 2015; Beisel, 1975; Dong et al., 2012). Here, we found that acetate 83 
accumulated in the peritoneal cavity of mice infected with Listeria monocytogenes, in a 84 
Staphylococcus aureus tissue-cage infection model, as well as in humans at sites of bacterial 85 
infection and inflammation (Figure 1A-C, Table 1). We next assessed how increased local 86 
acetate levels per se impacted numbers of memory CD8+ T cells in the peritoneal cavity. To 87 
this end, mice previously infected with Listeria monocytogenes expressing an OVA-peptide 88 
(LmOVA) were injected intra-peritoneally (i.p.) with 10 mM acetate. Twenty-four hours after 89 
acetate injection, peritoneal CD8+ T cell numbers in acetate treated mice were significantly 90 
increased as compared to mice injected with PBS (Figure 1D). Most of these cells expressed 91 
phenotypic markers of memory CD8+ T cells (Figure S1A). Re-challenging these mice i.p. in 92 
presence vs. absence of i.p.-applied acetate, also resulted in a significant acetated-dependent 93 
increase of CD8+ T cells in the peritoneal fluid (Figure 1E). To assess the relation between in 94 
vivo accumulation of acetate at sites of inflammation and CD8+ T cell counts, we analyzed left-95 
over human fluid samples collected for clinical indications, as well as murine Staphylococcus 96 
aureus tissue-cage fluids. In both, human and murine samples, CD8+ T cell numbers and 97 
acetate abundance correlated positively up to approximately 100 mM. Beyond 100 mM of 98 
acetate, CD8+ T cell numbers started to decline (Figure 1F,G). More than 60% of the CD8+ T 99 
cells recovered from tissue-cage fluid had a memory phenotype (Figure S1B). We then asked 100 
what the metabolic consequences of exposure to increased acetate abundance at sites of 101 
inflammation might be on CD8+ T cells. Specifically, we tested how ACSS1 and ACSS2 were 102 
impacted in CD8+ T cells 24 h after i.p. injection of 100 mM of acetate, as well as 24 h after 103 
i.p. re-challenge of mice previously infected with LmOVA. In both models, transcript 104 
abundance of the acetate assimilating enzymes was reduced by approximately 50% (Figure 105 
1H,I). Memory-like CD8+ T cells can be generated in vitro, using an established protocol 106 
(Figure S1C) (van der Windt et al., 2012; Balmer et al., 2016). In such in vitro generated murine 107 
memory OT-I T cells, already after 4 h of acetate exposure, reduced abundance of ACSS1 and 108 
ACSS2 mRNA started to become apparent (Figure S1D-E). At the site of infection, cognate 109 
memory CD8+ T cell activation occurs. We therefore also probed the effect of antigen-specific 110 
activation of murine memory OT-I T cells on transcript abundance of ACSS1 and ACSS2, in 111 
vitro. Both transcripts were strongly suppressed upon cognate re-stimulation (Figure 1J,K). 112 
Similar findings were made when activating human effector memory CD8+ T cells in presence 113 
of acetate (Figure S1F,G). 114 
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In all, these data identified high levels of acetate at sites of inflammation/infection, positively 115 
correlating with increased CD8+ T cells counts up to 100mM. We previously reported that 116 
acetate rapidly increased in the circulation of infected mice, and that, acutely, memory CD8+ 117 
T cells assimilate acetate in an ACSS2-dependent manner – which leads to catalyzed glycolysis 118 
and increased IFN- production (Balmer et al., 2016). We now find that exposure of CD8+ T 119 
cells to further increased acetate concentrations – which we show to occur at sites of 120 
infection/inflammation – evoked downregulation of ACSS1 and ACSS2, a phenomenon further 121 
accentuated by TCR activation. The experimental set-up capturing these scenarios – which, in 122 
vivo, plausibly form a continuum – are summarized in Figure 1L. 123 
Acetate promotes glutaminolysis by enhancing glutaminase enzymatic activity 124 
To further dissect the metabolic profile of memory CD8+ T cells exposed to increased acetate 125 
levels at sites of infection, we analyzed murine memory OT-I T cells in a metabolic flux 126 
analyzer. Supplementation of acetate resulted in a significant increase in oxygen-127 
consumption rates (OCR) compared to medium control, whereas glycolysis was unchanged 128 
(Figure 2A and Figure S2A). Furthermore, re-stimulation of memory OT-I T cells with OVA-129 
peptide in presence of acetate also increased OCR when compared to medium control (Figure 130 
S2B). Addition of 13C-acetate to memory OT-I T cells revealed that carbon derived from 131 
labelled acetate was found in only low amounts in citrate of memory cells stimulated with 132 
OVA (Figure 2B, left panel). Albeit only low in abundance also in non-activated cells, acetate-133 
derived carbons were consistently reduced also in other intermediates of the TCA cycle 134 
(Figure 2B, right three panels). Of note, also expansion of acetate-fueled acetyl-CoA was much 135 
reduced upon OVA-activation of memory CD8+ T cells (Figure 2C). These data indicated that 136 
(i) acetate assimilation was blunted in these re-stimulated memory cells, and (ii) increased 137 
OCR was not primarily resulting from increased fueling of acetate into the TCA-cycle (Figure 138 
2D). We noted, however, that the presence of acetate was associated with a higher overall 139 
abundance of -ketoglutarate, fumarate and malate, hinting at the possibility of 140 
glutaminolysis derived glutamate as a carbon-source entering the TCA-cycle (Figure 2B,D). To 141 
test this hypothesis, 13C-glutamine tracing experiments were performed, which confirmed an 142 
increase of glutamine-derived carbons in glutamate (m+5) in the presence of acetate, both in 143 
non-activated and re-stimulated murine memory CD8+ T cells (Figure 2E, Figure S2C). This 144 
suggested that in this scenario acetate promoted increased glutaminolysis, TCA activity, and 145 
interlinked oxidative phosphorylation in memory CD8+ T cells. Indeed, BPTES, an inhibitor of 146 
glutaminolysis, suppressed acetate-augmented OCR in murine and human memory CD8+ T 147 
cells (Figure 2F and Figure S2D). BPTES alone, as well as inhibition of ATP-citrate lyase did not 148 
affect OCR (Figure S2E,F). Notably, addition of acetate up to a concentration of 50-100 mM 149 
increased human and murine CD8+ T cell viability (Figure 2G, Figure S2G), a feature that was 150 
lost in absence of glutamine in the cell culture medium (Figure 2H, Figure S2H), or in presence 151 
of BPTES (Figure S2I). These data indicated that acetate-augmented glutaminolysis promoted 152 
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increased cell respiration and viability. At sites of high acetate concentration in vivo, altered 153 
migratory behavior could further contribute to increased CD8+ T cell numbers. We therefore 154 
also assessed spontaneous as well as CXCL12-directed migration of murine memory OT-I T 155 
cells in presence or absence of acetate in transwell assays. In a dose dependent manner, 156 
acetate inhibited spontaneous migration compared to medium control (Figure 2I), and also 157 
somewhat blunted their chemokine-directed translocation (Figure 2J). These experiments 158 
indicated that, rather than being assimilated by members of the ACSS-family and entering 159 
core metabolism, or providing acetyl-groups for acetylation reactions (Comerford et al., 2014; 160 
Balmer et al., 2016), at the site of infection acetate modulated cellular metabolism, survival 161 
and migration in a different way. 162 
To elucidate how acetate mediated increased glutaminolysis in memory CD8+ T cells, we 163 
measured expression of glutaminase (GLS), which converts glutamine to glutamate. Addition 164 
of acetate did not change overall abundance of GLS transcript or protein (Figure S2J-L). By 165 
contrast, glutaminase activity was significantly increased in memory CD8+ T cells exposed to 166 
acetate (Figure 2K). To dissect whether the acetate-mediated increase in glutaminase activity 167 
was a direct or indirect effect, we analyzed the activity of recombinant human glutaminase in 168 
presence vs. absence of acetate. These experiments revealed a direct and dose dependent 169 
effect of acetate on glutaminase-activity (Figure S2M), which is in line with a previous 170 
publication proposing an increase in glutaminase-activity by direct binding of acetate to the 171 
enzyme (O'Donovan and Lotspeich, 1966). To rationalize this pharmacological effect, we used 172 
in silico ligand docking of acetate into human glutaminase co-crystalized with bound 173 
glutamine. This identified four closely located docked-pose clusters, three of which lay close 174 
to the activation loop and one close to the substrate binding pocket (Figure 2L, upper panel). 175 
Of these, clusters I and II contained the greatest number of energetically favorable poses 176 
(7/10) and predicted interactions with residues that are known to affect the actions of other 177 
allosteric activators (Ferreira et al., 2013; Li et al., 2016). For example, the allosteric activator 178 
phosphate is similarly located in the mouse apo structure and its actions are strongly affected 179 
by mutation of residues G320 (G315 in 3VP0) and K325 (K317 in 3PV0) in humans (Figure 2L, 180 
middle panel) (Ferreira et al., 2013; Li et al., 2016). E. coli and B. subtilis both display poor 181 
amino acid conservation in this region of the enzyme and would be predicted not to be 182 
affected by acetate (Figure 2L, lower panel). When tested we found that, indeed, acetate did 183 
not enhance E. coli glutaminase activity but even decreased it (Figure S2N) (Brown et al., 184 
2008; Stalnecker et al., 2017). To test, at the molecular level, the requirement of K317 for 185 
acetate to function as allosteric activator (Figure 2L, middle and lower panel), wild type 186 
recombinant human glutaminase (2 versions: one commercially available, one mutation-187 
experiment control) and K317->A317 mutated recombinant glutaminase were used. Again, 188 
activity of wild type glutaminase was augmented by addition of acetate (20 mM), whereas 189 
K317->A317 mutated glutaminase was unaffected – establishing essentiality of K317 for 190 
acetate's activity augmenting property (Figure 2M). In all these data indicated that, upon 191 
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recall, acetate promoted glutaminolysis by direct allosteric effects that increase glutaminase 192 
activity. 193 
Acetate suppresses TCR-re-stimulation by reducing calcium-flux 194 
We next wondered how differential acetate handling of memory CD8+ T cells re-engaging with 195 
cognate antigen related to their functionality. To begin to address this question, memory OT-196 
I T cells were re-stimulated with OVA-peptide in presence/absence of acetate, and calcium-197 
flux was measured by flow-cytometry. Acetate significantly suppressed calcium-flux upon 198 
OVA re-stimulation in a dose-dependent manner (Figure 3A), suggesting decreased TCR-199 
stimulation. Accordingly, glycolytic switching and IFN- production were suppressed in 200 
presence of acetate in a dose-dependent manner in both murine and human memory CD8+ T 201 
cells (Figure 3B-F), whereas production of TNF was unchanged (Figure S3A). Notably, calcium 202 
add-back was able to correct acetate-mediated suppression of IFN-(Figure S3B). We 203 
reasoned that negatively charged acetate may interfere with biologically active (i.e. free) 204 
calcium, which would provide a mechanistic basis to the observed effect of acetate on 205 
calcium-flux. We thus measured free calcium levels in the absence and in increasing 206 
concentrations of acetate, in vitro. To exclude protein-modifications by acetate, we used PBS 207 
as solute. In effect, free calcium-levels dropped in presence of acetate in a concentration-208 
dependent manner (Figure 3G). Conversely, phosphate concentrations significantly increased 209 
(Figure 3H). To assess whether acetate depleted calcium-levels also in vivo, we determined 210 
free calcium levels in murine and human fluids sampled from infectious and inflamed sites. 211 
Calcium levels were significantly depleted in both, human infected and sterile inflamed body 212 
fluids, and infected murine peritoneal fluids in presence of acetate (Figure 3I,J). Inversely, 213 
phosphate-levels were increased in murine S. aureus skin infection and in inflamed human 214 
body fluids (Figure 3 K,L). To elucidate whether decreased calcium levels were responsible for 215 
reduced calcium-flux upon TCR re-stimulation, we added excess calcium to acetate-exposed 216 
memory OT-I T cells upon OVA re-stimulation. Addition of 10 mM calcium was sufficient to 217 
normalize calcium-flux back to control conditions (Figure 3M, Figure S3C). Addition of 10 mM 218 
calcium was also sufficient to augment memory OT-I T cell migration, indicating that impaired 219 
cell activation and migration in presence of acetate may be related to calcium-depletion in 220 
the presence of acetate (Figure S3D). Of note, also in absence of glutamine, acetate reduced 221 
IFN- production by memory OT-I T cells, indicating that the effect of acetate on glutaminase-222 
activity and its effect on calcium-flux are distinct (data not shown). These data established 223 
that acetate suppressed memory CD8+ T cell re-call responses as a consequence of reduced 224 
calcium availability when present during re-stimulation. To directly capture acetate’s time- 225 
and concentration dependent immune augmenting vs. immuno-suppressive features, a time 226 
course experiment encompassing both features of this metabolite was performed (Figure 227 
3N). 228 
Acetate suppresses immunopathology at sites of infection and modulates tissue-remodeling 229 
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We went on and asked how, at the site of infection, acetate-mediated metabolic and 230 
functional re-programming of memory CD8+ T cells modulated immune-control. To address 231 
this question, we re-infected mice, previously infected with LmOVA, i.p. in presence or 232 
absence of 10 mM acetate also administered i.p. at the same time as the pathogen. Similar to 233 
our previous findings, acetate promoted superior immune-control as measured by bacterial 234 
loads in the liver and in the spleen (Figure 4A). However, immunopathology determined by 235 
local lactate dehydrogenase-levels, as well as peritoneal IFN-, was suppressed in presence of 236 
acetate (Figure 4B,C). Peritoneal concentrations of IL-10 tended to be elevated in presence of 237 
acetate, indicating a possible immunomodulatory role of acetate (Figure S4A). Increased 238 
expression of PD-L1 on CD8+ T cells recovered from peritoneal fluid would also align with this 239 
notion (Figure S1A). Histologically, peritoneal thickness – as another measure of 240 
immunopathology (Mizuno et al., 2009) – was also reduced in presence of acetate (Figure 241 
4D). To further characterize a potential immunomodulatory role of acetate at the site of 242 
infection, we performed a PCR-array from peritoneal tissue of mice re-challenged with 243 
LmOVA in presence or absence of acetate. This experiment revealed increased TGF- 244 
transcript levels in the peritoneum from acetate treated mice, whereas transcripts of the pro-245 
inflammatory cytokines Ifng, Tnf, as well as transcripts of integrin- and collagen-family genes 246 
were decreased in presence of acetate (Figure 4E and Figure S4B). Overall, these experiments 247 
suggested that, at the site of infection, acetate suppressed immunopathology. 248 
Taken together, our data indicated that at sites of infection acetate catalyzed glutaminolysis 249 
in memory CD8+ T cells, augmenting mitochondrial respiration and cell survival. Further, by 250 
altering availability of free calcium, acetate suppressed TCR-triggered calcium-flux, glycolytic 251 
switching and IFN- production. In a time-resolved manner, acetate’s glycolysis boosting 252 
capacity (Balmer et al., 2016) and the herein described effects were balancing pathogen 253 
clearance against immunopathology (Figure 4F).  254 
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Discussion 255 
The metabolic environment has been shown to critically impact the outcome of immune 256 
responses. Probably the best characterized example is the tumor microenvironment which 257 
shapes immune cell metabolism and function. Here we show that acetate levels accumulate 258 
at sites of infection and reprogram memory CD8+ T cell metabolism and function by boosting 259 
glutaminolysis and altering availability of calcium. Acetate levels can rise up to about 5 mM 260 
in the circulation upon systemic bacterial infection in mice (Balmer et al., 2016). At the site of 261 
infection, acetate levels are initially low but then can reach >100 mM. This implies that 262 
memory T cells are exposed to rising acetate concentrations at inflamed sites where they are 263 
likely to re-encounter antigen. While acute, transient exposure of ACSS competent memory 264 
CD8+ T cells to acetate levels of 5 mM boosted glycolysis and cytokine secretion (Balmer et 265 
al., 2016), acetate also mediated a decrease of its assimilation machinery (i.e. ACSS1 and 2). 266 
Non-metabolized acetate on the one hand augmented glutaminase enzymatic activity, fueling 267 
the TCA-cycle and mitochondrial respiration, thereby supporting cell viability. On the other 268 
hand, acetate present during antigen re-encounter reduced free calcium abundance, thus 269 
suppressing migration and TCR-triggered calcium flux, and subsequent effector function. This 270 
indicates that, before reaching the site of infection, memory CD8+ T cells are boosted and thus 271 
prepared for rapid pathogen removal at acutely infected sites (Balmer et al., 2016). However, 272 
at the site of unresolved inflammation where acetate abundance is steadily increasing, their 273 
inflammatory capacity is gradually being suppressed – thereby balancing pathogen clearance 274 
and immunopathology. Depending on timing of exposure, the same metabolite – acetate – 275 
thus has opposing effects on memory CD8+ T cells: in transit to the site of infection acetate is 276 
used to acetylate and catalyze GAPDH, enhancing glycolytic switch and interlinked 277 
inflammatory output of memory CD8+ T cells early upon re-stimulation (i.e. when re-278 
stimulated in low acetate abundance). At sites of prolonged inflammation, where acetate 279 
gradually accumulates, cells lose their capacity to assimilate acetate, acetate catalyzes 280 
glutaminase activity and develops suppressive capacity by 'buffering' calcium (Figure 4F). 281 
Mechanistically, acetate's effects on glutaminase-activity and calcium-flux are distinct. 282 
However, functionally they may well complement each other. Initially, prolonged survival 283 
allows for sufficient cell-numbers available for efficient pathogen-clearance, while later on 284 
this may support accumulation of inflammation resolving mediators. 285 
Immunopathology plays a key role in many infectious and inflammatory diseases, 286 
contributing to morbidity and mortality. For example, during viral infections cytotoxic CD8+ T 287 
cells, while effectively killing infected cells, can also cause non-specific, tissue-destructive 288 
inflammation (Rouse and Sehrawat, 2010). Likewise, immunopathology mediates 289 
autoimmune and chronic inflammatory diseases, such as inflammatory bowel disease. In the 290 
intestine, acetate-concentrations reach up to 200 mM/kg wet weight (Farrukh, 2010; 291 
Høverstad and Midtvedt, 1986), and were significantly reduced in patients with inflammatory 292 
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bowel disease, indicating that these high acetate-concentrations contribute to host-microbial 293 
mutualism and may protect from immunopathology (Farrukh, 2010). 294 
Acetate is a short-chain fatty acid abundantly produced by the gut microbiota via 295 
fermentation of dietary fibers (Tremaroli and Bäckhed, 2012). However, also germ-free 296 
animals readily increase serum acetate-levels upon metabolic stress, indicating efficient 297 
release of acetate from endogenous sources (Balmer et al., 2016). Further, we previously 298 
demonstrated that rising systemic acetate-levels also upon systemic bacterial infection are 299 
not primarily bacteria-driven, since also systemic infection with bacteria genetically incapable 300 
for acetate-production induced stress-levels of acetate in the host (Balmer et al., 2016). The 301 
source, or sources, of increased local acetate levels observed in this study thus remain 302 
unclear. Since also at sterile inflammatory sites acetate abundance was increased, a bacterial-303 
origin seems unlikely. Given the large amount of cell death within any inflammatory area, one 304 
possibility could be the accumulation of extracellular acetate that is released from 305 
intracellular sources upon cell death. 306 
In conclusion, our data demonstrate that acetate can function as a rheostat of the immune 307 
response, balancing pro- and anti-inflammatory properties during the course of an immune 308 
response. Opposing effects on immune cell function driven by a single metabolite through 309 
distinct cellular metabolic effects emphasize the need to consider metabolic reprogramming 310 
in a time- and context resolved manner. 311 
Limitations of Study 312 
The molecular mechanisms by which acetate and TCR signaling drive downregulation of 313 
ACSS1 and ACSS2 remain to be defined. Also, we could not measure memory CD8+ T cell 314 
metabolism in real time in vivo during the course of an infection, but focused on ex vivo 315 
analyses. Finally, while we found increased accumulation of acetate at sites of inflammation 316 
also in humans, how memory CD8+ T cell metabolism is regulated at these sites needs to be 317 
explored.  318 
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Figure legends 336 
Figure 1: Acetate-levels are up to 100-fold increased at sites of infection and suppress ACSS1 337 
and ACSS2 expression in CD8+ T cells. A) Acetate levels in the peritoneal fluid, 24 h after i.p. 338 
LmOVA-infection in C57BL/6 mice. B) Acetate levels in tissue cages at the indicated time-339 
points following S. aureus infection. C) Acetate levels in human infected body fluids 340 
(abscesses) as compared to non-inflamed control fluids. D) CD8+ T cell numbers in the 341 
peritoneal fluid 24 h upon i.p.-administration of 10 mM acetate in LmOVA-immunized mice. 342 
E) CD8+ T cell numbers in the peritoneal fluid 24 h upon i.p. re-infection with LmOVA +/- 10 343 
mM acetate in LmOVA-immunized mice. F and G) Absolute numbers of CD8+ T cells recovered 344 
from locally infected fluids shown in (B) and (C) as determined by flow cytometry. H and I) 345 
Expression of ACSS1 and ACSS2 in MACS-purified CD8+ T cells from the peritoneal cavity of 346 
LmOVA-immunized mice upon injection of 100 mM acetate (H) or re-challenged with LmOVA 347 
(I). J and K) Expression of ACSS1 (J) and ACSS2 (K) in murine memory OT-I T cells upon OVA-348 
stimulation for 4 h in presence or absence of the indicated acetate-concentrations. L) 349 
Experimental set-up mimicking the time-course of acetate-exposure of memory CD8+ T cells. 350 
Each dot represents one mouse or sample, lines indicate means. Error bars are SD. Dashed 351 
lines indicate the detection limit. T-test (A, C, D, E), One-way ANOVA (B and F) and Two-way 352 
ANOVA (H-K) were used to compare the groups. * P < 0.05, ** P < 0.01, **** P < 0.0001 353 
Figure 2: Acetate promotes glutaminolysis by enhancing glutaminase enzymatic activity. A) 354 
Memory OT-I T cells were analyzed by metabolic flux analysis upon injection of 5 mM acetate 355 
(blue) or medium control (black) at the beginning of the analysis (dashed line and arrow). 356 
Shown is a representative experiment of OCR-values and pooled data from 5 independent 357 
experiments showing OCR-values at 300 min post-injection. B and C) 13C-acetate tracing 358 
experiment of murine memory OT-I T cells. Cells were incubated  +/- 5 mM 12C-acetate (blue) 359 
and +/- 10 µM OVA-peptide for 6 h and then all traced with 13C-acetate for 6 h. B) Filled bars 360 
represent contribution of 13C-acetate to the respective metabolite-pool. C) Relative 361 
abundance of m+2 acetyl-CoA from 13C-acetate. D) Schematic of mitochondrial metabolism 362 
and possible effects of acetate. E) Same experiment as in (B), but with 13C-glutamine. The 363 
different colors indicate the number of radiolabeled carbons detected in glutamate. F) 364 
Memory OT-I T cells were pre-incubated for 2 h in presence (red) or absence (black) of the 365 
glutaminolysis-inhibitor BPTES or vehicle control. Cells were then analyzed by metabolic flux 366 
analysis upon injection of 5 mM acetate (dashed line and arrow). Shown is a representative 367 
experiment of OCR-values and pooled data from 4 independent experiments assessing the 368 
net-increase in OCR between time-point 30 and 150 min. G and H) Viability of murine memory 369 
CD8+ T cells cultured in vitro for 3 days in presence (G) or absence (H) of glutamine and 370 
increasing acetate-concentrations as determined by flow cytometry (% Annexin V and PI 371 
negative). I and J) Spontaneous (I) and chemokine-directed (J) migratory capacity of in vitro 372 
generated murine memory OT-I T cells analyzed in a transwell-assay in increasing 373 
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concentrations of acetate. K) Glutaminase activity in murine memory OT-I T cell extracts 374 
exposed for 4 h to the indicated acetate-concentrations. L) Upper panel: a wireframe 375 
representation of the four docked pose clusters identified in our study is shown in one of the 376 
four subunits of the enzymatically active homo-tetramer of glutaminase. Middle: An example 377 
docked-pose from cluster I, showing predicted hydrogen bond interactions (dashed orange 378 
lines) between acetate and the side chains of residues S319 (314) and K235 (317). The green 379 
molecule is bound glutamine. Bottom: an alignment showing the poor amino acid 380 
conservation in the predicted allosteric activation region of human (from the 3PV0 crystal 381 
structure used here) and prokaryotic glutaminase (P77454, E. coli; O31465, B. subtilis). The 382 
gray shade highlights S314 and K317. M) Glutaminase activity of human recombinant 383 
glutaminase (rh), wildtype human glutaminase (wt = mutation control) and human 384 
glutaminase with a K->A mutation at position 317, depicted in the lower panel of (L), assessed 385 
in presence or absence of 20 mM acetate. 386 
Each dot represents one mouse or human, lines indicate means, error bars are SD. T-test (A, 387 
F), One-way ANOVA (G, H, I, K) or Two-way ANOVA (B, C, J, M) were used to compare the 388 
groups. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 389 
Figure 3: Acetate suppresses TCR-re-stimulation by reducing calcium availability. A) Calcium 390 
flux as assessed by flow cytometry of murine memory OT-I T cells cultured in presence (blue) 391 
or absence of acetate (black) for 30 min. One representative experiment (left) and pooled 392 
data from 2-3 independent experiments (right) are shown. B) Glycolytic switch upon OVA-393 
injection with (blue) or without (black) acetate in murine memory OT-I T cells as assessed by 394 
metabolic flux analysis. One representative experiment (left) and pooled data from 4 395 
independent experiments (right) are shown. The glycolytic switch was calculated by 396 
subtracting the basal ECAR from maximal ECAR. The dashed line indicates the time of OVA 397 
(+/- acetate) injection. C and D) IFN- production as assessed by intracellular cytokine staining 398 
in murine (C) or human (D) memory CD8+ T cells 4 h after re-stimulation with 10 µM OVA-399 
peptide or anti-CD3/CD28 antibodies in presence (blue) or absence (black) of indicated 400 
acetate-concentrations. E and F) IFN- mRNA (E) and protein (F) in human memory CD8+ T 401 
cells 4 h after re-stimulation with anti-CD3/CD28 antibodies in presence (blue) or absence 402 
(black) of indicated acetate-concentrations. G and H) Calcium- (G) and phosphate-levels (H) 403 
assessed in vitro in presence (blue) or absence (black) of the indicated acetate-404 
concentrations. I-K) Calcium- (I and J) and phosphate-levels (K and L) in human and murine 405 
fluids as described in Figure 1A-C. M) Calcium-flux as described in (A) was assessed in 406 
presence (blue) or absence (black) of acetate and additional calcium. N) IFN- production as 407 
assessed by intracellular cytokine staining in murine memory OT-I T cells either exposed to 408 
acetate prior or during OVA-re-stimulation for 4 h. 409 
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Each dot represents one mouse or human, lines indicate means, error bars are SD. T-test (B, 410 
I, J, L), One-way ANOVA (G, H, K, M, N) or Two-way ANOVA (C-F) were used to compare the 411 
groups. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 412 
Figure 4: Acetate suppresses immunopathology at sites of infection and modulates tissue-413 
remodeling. A) LmOVA-immunized mice were i.p. re-infected with 105 CFU LmOVA in 414 
presence (blue) or absence (black) of 10 mM acetate and bacterial burdens in spleen and liver 415 
were assessed by bacterial plating 24 h post-infection. B) LDH levels in the peritoneal fluid of 416 
mice described in (A) were analyzed using a commercially available assay kit. C) IFN- levels 417 
in the peritoneal fluid of mice described in (A) were determined by cytometric bead array. D) 418 
Peritoneal morphology on formalin-fixed, paraffin-embedded samples stained with elastica 419 
van Gieson. Shown are representative samples of one control (Ctr) and one acetate-treated 420 
(Ac) animal. Peritoneal thickness was quantified (right panel). E) Volcano plot of PCR-array 421 
analysis of the peritoneal samples shown in (D). Red-highlighted genes were upregulated, 422 
green-highlighted genes down-regulated in presence of acetate. F) Schematic depiction of the 423 
proposed model of acetate, playing opposing roles during an immune response in a time and 424 
context dependent manner. 425 
Each dot in A-D represents one mouse. Shown are pooled data from 2 independent 426 
experiments with 3-7 animals per group. Lines indicate means, error bars are SD. Dashed lines 427 
in A and C indicate the detection limit. T-test was used to compare the groups. * P < 0.05, ** 428 
P < 0.01 429 
Table 1: Patient characteristics  430 
Gender (f/m) 6 / 5  
Age (mean, years) 51 
Source (n)  
     abscess/cyst 7 
     wound 1 
     ascites 1 
     synovia 2 
Pathogen isolated (n)  
     Staphylococcus aureus 1 
     Staphylococcus epidermidis 1 
     mixed 4 
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RESOURCE AVAILABILITY  431 
Lead Contact  432 
Further information and requests for resources and reagents should be directed to and will 433 
be fulfilled by the Lead Contact, Christoph Hess (ch818@cam.ac.uk; chess@uhbs.ch). 434 
Materials Availability  435 
This study did not generate new unique reagents.  436 
Data and Code Availability  437 
The published article includes all datasets generated or analyzed during this study.  438 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  439 
Animal husbandry 440 
Male and female C57BL/6 or MHC class I-restricted OVA-specific T cell receptor (OT-I) 441 
transgenic mice were 6-8 weeks of age and housed in IVC cages on racks in a room with 442 
controlled temperature (22-24°C) and humidity (40-60%). Mice were maintained on a 12 hour 443 
light-dark cycle. All mice were fed a standard diet (Kliba AG, #3436 EX). Health checks were 444 
conducted on all mice at least once daily. For experimental control groups, littermates were 445 
used. All animal experiments were approved by the Animal Care Committee of the Veterinary 446 
Office Basel, Switzerland. 447 
Human abscess fluids 448 
Human abscess fluids were obtained from the division of Clinical Microbiology of the 449 
University Hospital Basel after informed consent of the patients and ethical approval of the 450 
ethics committee of both Basels. As controls, non-inflamed samples (e.g. sterile ascites, cyst-451 
fluids, pleural transudate) were used. Samples were stored at 4°C prior to measurement. 452 
Patient characteristics are summarized in Table 1.  453 
Isolation of human effector memory (EM) CD8+ T Cells 454 
Peripheral blood mononuclear cells were isolated by standard density-gradient centrifugation 455 
protocols (Lymphoprep; Fresenis Kabi) from healthy male and female blood donors, >18 years 456 
of age. Results were not stratified by age or sex, since we did not have this information at the 457 
time of analysis. MACS beads and LS columns (both Milteny Biotec) were used to sort CD8+ 458 
positive T cells. The positively selected CD8+ T cells were incubated with APC anti-CD62L mAb 459 
(ImmunoTools) and Pacific Blue anti-CD45RA (Beckman Coulter) and sorted by flow cytometry 460 
(BD FACSAria III or BD Influx Cell Sorter). Experiments using blood donor derived cells were 461 
approved by the blood transfusion service of the Swiss Red Cross. 462 
Cell culture 463 
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Primary cells of male and female mice were cultured in RPMI medium (RPMI 1640 containing 464 
10% FCS, 100 U/mL penicillin, 100 µg streptomycin, 0.29 mg/mL L-glutamine, 50 µM 2-465 
Mercaptoethanol) at 37°C and 5% CO2. 466 
METHOD DETAILS  467 
In vitro memory differentiation 468 
Memory OT-I T cells were generated as described previously (Balmer et al., 2016; van der 469 
Windt et al., 2013). Briefly, the lymph nodes from MHC class I-restricted OVA-specific T cell 470 
receptor (OT-I) transgenic mice  and the spleen of C57BL/6 mice were aseptically removed 471 
and incubated in liberase TL (Roche) for 30 min. After mashing through a 70 µm cell strainer 472 
(BD Biosciences), red blood cells were lysed with RBC Lysis Buffer Solution (eBioscience). The 473 
isolated cell suspensions were washed in RPMI medium (RPMI 1640 containing 10% FCS, 100 474 
U/mL penicillin, 100 µg streptomycin, 0.29 mg/mL L-glutamine, 50 µM 2-Mercaptoethanol 475 
(Life Technologies)) and re-suspended to 106 cells/ml. The splenocytes and OT-I cells were 476 
pooled in a ratio of 1:1 and activated with OVA peptide (Eurogentec) at 10-9 M at 37°C for 3 477 
days. The cells were then washed and re-suspended to 2 x 106 cells/ml and cultured in the 478 
presence of IL-15 (10 ng/ml) at 37°C for another 3 days to generate OVA-specific memory 479 
CD8+ T cells. Phenotyping was performed using BUV395-anti CD44 (BD), APC-anti CD8, BV421-480 
anti KLRG1, PE-anti-CD62L, APC-Cy7-anti CD43, BV421-anti PDL1, PE-anti-CD25, BV510-anti 481 
CD27 (all Biolegend) and PE-Cy5-anti CD127 (eBioscience). 482 
Acetate measurement in murine and human samples 483 
Acetate concentrations in peritoneal fluids and human samples were determined using the 484 
acetate fluorimetric assay kit (Bioassay Systems), following the manufacturer's instructions. 485 
Measurement of cell viability 486 
To measure the viability, 105 mouse or human memory CD8+ T cells were plated in a 96-well 487 
plate in RPMI medium. The cells were incubated at 37C for up to 7 days. The cells were 488 
washed in Annexin V Binding Buffer (BD Pharmingen) and stained with APC Annexin V 489 
(ImmunoTools) and PI (Sigma Aldrich). Samples were acquired on an Accuri® C6 Flow 490 
Cytometer and analyzed with FlowJo-Software (FlowJo 10.2). Viable cells were defined as 491 
Annexin V and PI double negative. Where indicated, cells were incubated in presence of BPTES 492 
(Sigma Aldrich) at 50 µM or in glutamine-free RPMI containing dialyzed FCS (Life 493 
Technologies). 494 
Transwell migration assay 495 
For the in vitro migration assay 2-5 x 105 cells were resuspended in 80% full medium and 20% 496 
PBS, supplemented with varying concentration of sodium acetate, calcium chloride and 497 
sodium chloride. 100 μL of cell suspension was seeded in 5 μm pore cell culture inserts (Sigma, 498 
CLS3421) with 500 μL of the corresponding medium in the well. After 3 h incubation at 37°C, 499 
the volumes in the insert and the well were measured with a pipette. The cell density was 500 
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measured by acquiring 30 µL of the insert and well with a CytoFlex flow cytometer (Beckman 501 
Coulter) by counting the number of events in the live gate using FlowJo. The translocation 502 
index was calculated by dividing the cell number of the cell culture insert with the total cell 503 
number. Every condition was assessed by technical triplicates and every experiment was 504 
repeated at least three times. Where indicated, CXCL12 (Peptrotech) at 50 ng/ml was used. 505 
Murine peritonitis model 506 
C57BL/6 mice were intra-peritoneally (i.p.) infected with 5000 CFU Listeria monocytogenes 507 
expressing the OVA-peptide (LmOVA). 28 days later, mice were re-infected with 105 CFU 508 
LmOVA i.p. in presence or absence of 5 mM acetate. Mice were sacrificed 24 h later and 509 
peritoneal fluid, spleen, liver and serum harvested. Spleens and livers were homogenized in 510 
0.5% Terigitol/PBS using a Tissuelyser (Qiagen) and sterile stainless-steel ball bearings. Organ 511 
suspensions were then plated on BHI agar-plates and colonies counted upon 24 h incubation 512 
at 37°C. Peritoneal fluids were centrifuged and the cells analyzed by flow-cytometry upon 513 
staining with FITC-anti-CD3, BUV395-anti CD44 (both BD), BV421-anti PDL1, APC-Cy7-anti 514 
CD43, BV510-anti CD27 and PE-anti CD8 antibodies, Zombie-Red viability staining (all 515 
Biolegend) or by RT-PCR upon MACS-purification and storage in Trizol Reagent (Thermo Fisher 516 
Scientific). Peritoneal fluids and sera were frozen at -80°C prior to further analysis. LDH 517 
concentrations in peritoneal fluids were measured using a commercially available assay kit 518 
(Abcam). All experiments were performed in accordance with local rules for the care and use 519 
of laboratory animals. 520 
S. aureus tissue cage model 521 
The mouse model of foreign-body infection (John et al., 2011; Nowakowska et al., 2014) was 522 
used in the present study. Briefly, a sterile tissue cage (Angst + Pfister AG, Zurich, Switzerland) 523 
was implanted subcutaneously in the back of female C57BL/6 mice, 13 weeks old (janvierlab, 524 
France). After complete wound healing (2 weeks), cages were tested for sterility by culturing 525 
the aspirated tissue cage fluid (TCF). Teflon cages were infected with 785 CFU of MSSA ATCC 526 
29213. The infection was confirmed at day 1 directly before treatment start by plating.  Mice 527 
were i.p. treated twice a day with 5% glucose for 11 days. Tissue cage fluid (TCF) was aspirated 528 
at different time points (day 3, 6, 9, 11 and 14) and apropriate dilutions were plated to 529 
determine the amount of planktonic MSSA. Tissue cage fluids were then analyzed for acetate, 530 
calcium and phosphate levels and CD8+ T cells isolated by MACS-purification and frozen in 531 
Trizol Reagent (Thermo Fisher Scientific). For phenotyping, cells were stained with APC-anti 532 
CD8 (Biolegend), BUV395-anti CD44 (BD), PE-anti CD62L (Biolegend) antibodies and Zombie-533 
Red Viability staining (Biolegend). 534 
Histology 535 
Small pieces (0.5 x 0.5 cm) of peritoneum were fixed in 4% formaldehyde for 24 h. Samples 536 
were then paraffin-embedded, cut, and stained with H&E and elastica van Gieson on an 537 
automated-stainer according to standard procedures. Peritoneal thickness was measured 538 
 18 
from the mesothelial surface to the border of the loose connective tissue between compact 539 
zone and muscular layer by a board-certified pathologist in a blinded manner as described in 540 
(Mizuno et al., 2009). 541 
Seahorse experiments 542 
Oxygen consumption rates (OCR, in pMoles/min) and extracellular acidification rates (ECAR, 543 
in mpH/min) were measured in plated cells (2.5 x 105 per well) kept in serum-free unbuffered 544 
RPMI-1640 medium (Sigma-Aldrich), under basal conditions, and in response to OVA-peptide 545 
(10 µM) or acetate (5 mM) injection using the instrument’s multi-injection ports. Where 546 
indicated, cells were pre-treated with the ACLY-inhibitor SB204990 (Tocris) at 30 µM or BPTES 547 
(Sigma Aldrich) at 50 µM 2 h prior to and during metabolic flux analysis or vehicle control. All 548 
data were generated using the XF-96 Extracellular Flux Analyzer (Seahorse Bioscience). 549 
Metabolic tracing 550 
GC-MS metabolite analysis was conducted as previously described (Blagih et al., 2015) 551 
(Balmer et al., 2016). Briefly, 5 x 106 IL-15 expanded OT-I memory cells were cultured in 552 
standard or glutamine-free RPMI (with 10% dialyzed FCS) containing 10 mM 1,2-[13C]-acetate 553 
or 10 mM 13C-glutamine (Cambridge Isotope Laboratories) for 6 h. Metabolites were 554 
extracted from cells using ice-cold 80% methanol, followed by sonication and removal of 555 
cellular debris by centrifugation at 4°C. Metabolite extracts were dried, derivatized as tert-556 
butyldimethylsilyl (TBDMS) esters, and analyzed via GC-MS as previously described (Faubert 557 
et al., 2014). Uniformly deuterated myristic acid (750 ng/sample) was added as an internal 558 
standard following cellular metabolite extraction, and metabolite abundance was expressed 559 
relative to the internal standard and normalized to cell number. Mass isotopomer distribution 560 
was determined using a custom algorithm developed at McGill University, CA (McGuirk et al., 561 
2013). 562 
Quantitative PCR 563 
Quantitative PCR for mouse ACSS1 and ACSS2 mRNA was done in triplicates with SYBR Green 564 
Supermix (Promega). The following primers were used: ms ACSS1 (forward 5’-565 
GTTTGGGACACTCCTTACCATAC-3’ and reverse 5’-AGGCAGTTGACAGACACATTC-3’), ms ACSS2 566 
(forward 5’-GTGAAAGGATCTTGGATTCCAGT-3’ and reverse 5’-CAGATGTTTGACCACAATGCAG-567 
3’) (both Invitrogen). The following primers were used to analyze glutaminase mRNA: 568 
Mm01257297_m1 (Thermo Fisher Scientific). IFNg mRNA was measured using primers 569 
Mm01168134_m1 (Thermo Fisher Scientific). As a housekeeping gene mouse 18S mRNA was 570 
measured using ms 18S primers (forward 5’-GGGAGCCTGAGAAACGGC-3’ and reverse 5’-571 
GGGTCGGGAGTGGGTAATTT-3’) (Microsynth). Quantitative PCR for human ACSS1 and ACSS2 572 
mRNA was done in triplicates with SYBR Green Supermix (Promega). The following primers 573 
were used: hs ACSS1 (forward 5’-CACAGGACAGACAACAAGGTC-3’ and reverse 5’-574 
CCTGGGTATGGAACGATGCC-3’), hs ACSS2 (forward 5’-AAAGGAGCAACTACCAACATCTG-3’ and 575 
reverse 5’-GCTGAACTGACACACTTGGAC-3’) (both Invitrogen). As a housekeeping gene 18S 576 
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was used (4310893E, Applied Biosystems). Peritoneal immunopathology was assessed using 577 
the mouse Wound Healing RT2 Profiler PCR Array following the manufacturer’s instructions 578 
(Qiagen). RNA-quality was checked prior to the assay using the Bioanalyzer RNA-kit (Agilent). 579 
Glutaminase activity assay 580 
To analyze the activity of glutaminase in memory CD8+ T cells, the Glutaminase Microplate 581 
Assay Kit (Cohesion Biosciences) was used. After incubation, cells (4 Mio) were sonicated in 582 
the assay buffer (40 µl) provided with the kit and then processed according to the 583 
manufacturer’s instructions. Recombinant human glutaminase at 1 µg/ml (R&D Systems) and 584 
glutaminase from E. coli at 6 U/ml (Megazyme) were tested in the Glutaminase Microplate 585 
Assay (Cohesion Biosciences). 586 
Glutaminase-acetate in silico docking 587 
We used a template of the human glutaminase co-crystallized with bound glutamine (PDB ID 588 
3VP0). The three-dimensional structure of acetate was constructed ab initio in Chem3D Pro 589 
v14.0 (CambridgeSoft, Cambridge, UK) and energy-minimized using the integrated MM2 force 590 
field. The binding site of acetate was defined as being within 20 Å of the centroid around the 591 
α-carbon of Y446, a centrally located residue that interacts with glutamine in the substrate 592 
binding site.  Acetate was docked as a flexible ligand into the ligand-occupied structure using 593 
GOLD Suite v5.7.0 (The Cambridge Crystallographic Data Centre, Cambridge, UK) with the 594 
GoldScore function and default settings. Ten docked poses were generated and visualised 595 
with PyMol v1.3. 596 
Glutaminase mutagenesis 597 
Human GLS2 was cloned into the multiple cloning site of a pGEX-4T-1 bacterial expression 598 
vector containing a C-terminal glutathione-S-transferase (GST) tag. The K253A variant was 599 
generated by site-directed mutagenesis which corresponds to the GLS1 sequence K->A shown 600 
in Figure 2L. The E. coli strain BL21(DE3) was then transformed with wild type or K253A 601 
mutant pGEX-4T-1-GLS2 vectors. Recombinant GLS2-GST was purified from bacterial cell 602 
lysate using GST hiTRAP and Superdex 200 columns and eluted in 5mM Tris, 150mM HCl 603 
buffer (pH 7.5). Wildtype and mutant glutaminase was used at a concentration of 1 µg/ml for 604 
measuring glutaminase activity as described above. 605 
Calcium flux 606 
In vitro differentiated memory OT-I T cells were loaded with 1 µM Fluo4 (Invitrogen) and 1 607 
µM Fura Red (Invitrogen) with indicated acetate or calcium concentrations for 30 min at 37°C. 608 
After washing, T cells were activated with 10 µM OVA-peptide under continuous acquisition 609 
using an Accuri C6 (BD) or Cytoflex (Beckmann coulter) flow cytometer. Analysis was 610 
performed with FlowJo software using kinetics tool (ratio of geometric mean fluorescence 611 
intensity of Fluo4/FuraRed) and Prism software. 612 
Calcium and phosphate quantification 613 
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Calcium and phosphate concentrations were measured in collaboration with the diagnostics 614 
department of the University Hospital Basel using a fotometric Assay (Cobas, Roche). For in 615 
vitro calcium-measurements, PBS was supplemented with increasing concentrations of 616 
acetate and calcium-concentrations measured immediately. 617 
Intracellular cytokine staining 618 
200,000 cells per condition were re-activated with CD3/CD28 beads (1:10) or OVA-peptide 619 
(10 µM) in presence or absence of the indicated concentrations of acetate or calcium for 4 h. 620 
Brefeldin A (Biolegend) was added after 1 h of incubation. Fixation and permeabilization with 621 
BD Cytofix/CytopermTM and BD Perm/WashTM was done according to the instruction of the 622 
manufactorer (BD Biosciences). Cells were then stained with FITC-anti-human IFN- (BD 623 
Biosciences) or FITC-anti-mouse IFN- (Biolegend), aquired on an Accuri® C6 Flow Cytometer 624 
and analyzed using FlowJo-Software (FlowJo 10.2). 625 
Cytrometric bead array 626 
Cytokine concentrations in cell culture supernatants and peritoneal fluids were determined 627 
using the LegendPlex cytrometric bead Array Th1-Pannel (Biolegend), according to the 628 
manufacturer’s instructions. 629 
Immunoblot analysis 630 
Memory T cells were lysed in RIPA buffer (Thermo Scientific) containing protease- and 631 
phosphatase-inhibitors (Roche, #05 892 970 001 and #04 906 837 001), and protein 632 
concentrations determined with a BCA protein assay kit (Thermo Scientific). Whole-cell 633 
lysates were separated by 4–20% SDS-PAGE and transferred to nitrocellulose or PVDF 634 
membranes. Membranes were probed with anti-glutaminase mAb (Protein Tech, #19958-1-635 
AP) and anti-actin mAb (Sigma #A1978). Blots were then stained with the appropriate 636 
secondary antibody (IRDye 800CW– conjugated goat polyclonal antibody to rabbit IgG (926-637 
32211) from LI-COR). The Odyssey imaging system (LICOR) was used for detection, and the 638 
ImageJ software (1.48v) for quantification. 639 
Quantification and statistical analysis 640 
Differences were analyzed for statistical significance using Prism 7 for Macintosh (GraphPad 641 
Software Inc.). The details of the tests carried out are indicated in each figure legend. Where 642 
data were approximately normally distributed, values were compared using either a Student's 643 
t test, one-way or two-way ANOVA. Where data were non-normally distributed Wilcoxon-644 
tests were applied. In all cases, p-values < 0.05 were considered significant.  645 
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Exposure of CD8+ T to circulation stress-levels of 
acetate, re-stimulation in absence of acetate -> 
mimicking entrance of these cells into acute 
inflammatory site with (at this early stage) low acetate 
abundance:
-> Acetate is assimilated and expands acetyl-CoA
-> acetylation of GAPDH
-> catalyzing glycolysis and interlinked IFNg production
PRO-INFLAMMATORY
(Balmer, Immunity 2016)
Re-stimulation of memory CD8+ T cells in presence 
of  acetate -> mimicking later-stage inflammatory site:
-> Acetate and TCR-signal driving shut down of 
    ACSS: acetate assimilation blocked
-> acetate dampening TCR driven calcium-flux
-> acetate directly binding and activating glutaminase
ANTI-INFLAMMATORY
(Balmer - current submission)
Figure 4
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
BUV395 rat anti-mouse CD44 BD Cat# 740215 
APC rat anti-mouse CD8 Biolegend Cat# 100712 
BV421 hamster anti-mouse KLRG1 Biolegend Cat# 138413 
PE rat anti-mouse CD62L Biolegend Cat# 104408 
APC-Cy7 rat anti-mouse CD43 Biolegend Cat# 121220 
BV421 rat anti-mouse PDL1 Biolegend Cat# 124315 
PE-Cy5 rat anti-mouse CD127 eBioscience Cat# 15-1271-82 
PE rat anti-mouse CD25 Biolegend Cat# 101904 
BV510 hamster anti-mouse CD27 Biolegend Cat# 124229 
FITC rat anti-mouse CD3 BD Cat# 555274 
PE rat anti-mouse CD8  Biolegend Cat# 100708  
APC mouse anti-human CD62L ImmunoTools Cat# 21819626 
Pacific Blue anti-CD45RA Beckman Coulter Cat# A86050 
Bacterial and Virus Strains  
Listeria monocytogenes expressing chicken Ovalbumin 
(AA134–387) 
Prof. Ed Palmer, 
University Basel, CH 
 
Biological Samples   
Human body fluids University Hospital Basel  
Chemicals, Peptides, and Recombinant Proteins 
Liberase TL Research Grade Roche Cat#05 401 020 001 
APC Annexin V Immunotools Cat#31490016 
BPTES Sigma Aldrich Cat#SML0601 
SB204990 Tocris Cat#4962 
Recombinant murine CXCL12 Peprotech Cat#250-20A 
Recombinant human glutaminase R&D Systems Cat#10115-GL-020 
Glutaminase from E. coli Megazyme Cat#E-GLUTEC 
Critical Commercial Assays 
Acetate fluorimetric assay kit BioAssay Systems Cat#EOAC-100 
LDH Assay Kit  Abcam Cat#ab102526 
Glutaminase Microplate Assay Kit Cohesion Biosciences Cat#CAK1065 
Experimental Models: Organisms/Strains 
Mouse: B6.129S6-Rag2tm1Fwa Tg(TcraTcrb)1100Mjb   Taconic Model #2334 




ms ACSS1 (forward 5’-GTTTGGGACACTCCTTACCATAC-3’ and 
reverse 5’-AGGCAGTTGACAGACACATTC-3’) 
Invitrogen This paper 
ms ACSS2 (forward 5’-GTGAAAGGATCTTGGATTCCAGT-3’ and 
reverse 5’-CAGATGTTTGACCACAATGCAG-3’) 
Invitrogen This paper 
Gls: Mm01257297_m1 Thermo Fisher Cat#4331182 
Ifng: Mm01168134_m1 Thermo Fisher Cat#4331182 
ms 18S primers (forward 5’-GGGAGCCTGAGAAACGGC-3’ and 
reverse 5’-GGGTCGGGAGTGGGTAATTT-3’) 
Microsynth This paper 
hs ACSS1 (forward 5’-CACAGGACAGACAACAAGGTC-3’ and 
reverse 5’-CCTGGGTATGGAACGATGCC-3’) 
Invitrogen This paper 
Key Resource Table
hs ACSS2 (forward 5’-AAAGGAGCAACTACCAACATCTG-3’ and 
reverse 5’-GCTGAACTGACACACTTGGAC-3’) 
Invitrogen This paper 
Human 18S  Applied Biosystems Cat#4310893E 
Recombinant DNA 
pGEX-4T-1-GLS2_WT (C-terminal GST) Genscript  
pGEX-4T-1-GLS2_K253A (C-terminal GST) Genscript  
Software and Algorithms 
FlowJo BD https://www.flowjo.co
m 
GOLD Suite v5.7.0 The Cambridge 
Crystallographic Data 




PyMol v1.3 Schrödinger https://pymol.org/2/ 
ImageJ  https://imagej.net/Wel
come 
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Supplementary Figure Legends 
Supplementary Figure 1: Effect of local acetate concentrations on memory CD8+ T cell 
phenotype, related to figure 1. A) Phenotype of MACS-purified CD8+ T cells 24 h upon LmOVA-
re-infection of LmOVA-immunized mice in presence (blue) or absence (gray) of 10 mM acetate 
as determined by flow cytometry. Shown are representative histograms and quantification of 
CD44+ CD8+ T cells and PD-L1 expression. The dashed lines indicate unstained controls. B) 
Phenotype of MACS-purified CD8+ T cells of S. aureus tissue cage infection from day 6 of 
infection. Shown is a representative dot plot of n=5 mice. C) Surface marker expression of in 
vitro generated memory OT-I T cells. The dashed line indicates unstained controls. D and E) 
Baseline ACSS1 (D) and ACSS2 (E) expression in murine memory OT-I T cells after 4 h of 
incubation in control (black) or 5 mM acetate (blue) medium. F and G) Human effector 
memory CD8+ T cells were re-stimulated with anti-CD3/CD28 for 4 h in presence/absence of 
the indicated acetate-concentrations or control medium. ACSS1 (F) and ACSS2 (G) expression 
was determined by RT-PCR. 
Each dot represents one mouse or human. Lines indicate means, error bars are SD. T-test (A, 
D and E) and Two-way ANOVA (F and G) was used to compare the groups. * P < 0.05, ** P < 
0.01, **** P < 0.0001 
Supplementary Figure 2: Increased glutaminolysis is important for viability and happens 
independently of glutaminase-expression, related to figure 2. A) Memory OT-I T cells were 
analyzed by metabolic flux analysis upon injection of 5 mM acetate (blue) or medium control 
(black) at the beginning of the analysis (dashed line and arrow). Shown is a representative 
experiment of ECAR-values (left) and pooled data from 5 independent experiments (right) 
showing ECAR-values at 300 min. B) Memory OT-I T cells were re-stimulated with 10 µM OVA-
peptide in seahorse in presence (blue) or absence (black) of 5 mM acetate (dashed line). 
Shown is a representative experiment of OCR-values (left) and pooled data from 5 
independent experiments (right) showing OCR-values at 300 min. C) 13C-glutamine tracing 
experiment of murine memory OT-I T cells cultured in presence or absence of 5 mM acetate 
for 4 h and analyzed upon 6 h of exposure to 13C-glutamine. Shown is the m+5 abundance of 
13C-glutamate. D) Human effector memory CD8+ T cells were pre-incubated in presence (red) 
or absence (black) of the glutaminase-inhibitor BPTES (50 µM) and subsequently analyzed by 
metabolic flux analysis upon injection of 5 mM acetate (dashed line) at the beginning of the 
analysis. Shown is a representative experiment of OCR-values (left) and pooled data from 4 
independent experiments (right) calculating the net-increase of OCR from time 30 to 150 min. 
E) Memory OT-I T cells were pre-incubated in presence (red) or absence (black) of the 
glutaminase-inhibitor BPTES (50 µM) and subsequently analyzed by metabolic flux analysis. 
Shown is a representative experiment of OCR-values (left) and pooled data from 5 
independent experiments (right) calculating the net-increase of OCR from time 30 to 150 min. 
F) Memory OT-I T cells were pre-incubated in presence (empty symbols) or absence (filled 
2 
symbols) of the ACLY-inhibitor SB204990 (30 µM) and subsequently analyzed by metabolic 
flux analysis upon injection of 5 mM acetate (blue) or medium control. Shown is a 
representative experiment of OCR-values (left) and pooled data from 3-5 independent 
experiments (right) calculating the net-increase of OCR from time 30 to 150 min. G-I) Viability 
of human effector memory CD8+ T cells cultured in vitro for 5 days in presence (G) or absence 
(H) of glutamine in the culture medium, or in presence of BPTES (I), and the indicated acetate-
concentrations. Viability was determined by flow cytometry using annexin V and PI staining. 
J-L) Murine (J and L) and human (K) memory CD8+ T cells were incubated in the indicated 
acetate-concentrations for 4 h and glutaminase-expression analyzed by RT-PCR (J and K) and 
immunoblotting (L). Data in (L) are normalized to actin-expression and 0 mM acetate. M) 
Glutaminase activity of human recombinant glutaminase incubated for 15 min with the 
indicated acetate-concentrations. N) Glutaminase activity was determined in E. coli derived 
glutaminase, incubated in presence or absence of acetate for 1 h using a commercially 
available assay kit.
Each dot represents one mouse or human, lines indicate means, error bars are SD. T-test (A-
E), Mann-Whitney test (N) or One-way ANOVA (F-M) were used to compare the groups. * P < 
0.05, ** P < 0.01, **** P < 0.0001 
Supplementary Figure 3: Acetate suppresses calcium-availability to memory CD8+ T cells and 
suppresses effector function, related to figure 3. A) TNF production as assessed by intracellular 
cytokine staining in murine (left) or human (right) memory CD8+ T cells 4 h after re-stimulation 
with 10 µM OVA-peptide or anti-CD3/CD28 antibodies in presence (blue) or absence (black) 
of indicated acetate-concentrations. B) IFN-g production as assessed by intracellular cytokine 
staining in murine memory OT-I T cells 4 h after re-stimulation with 10 µM OVA-peptide in 
presence or absence of 20 mM acetate or 10 mM calcium. Data are normalized to the non-
stimulated samples of each condition. C) Calcium-flux of the cells as treated in (B). D) 
Spontaneous migratory capacity of in vitro generated murine memory OT-I T cells analyzed in 
a transwell-assay in presence or absence of the indicated acetate and calcium-concentrations. 
Each dot represents one mouse or human, lines indicate means, error bars are SD. One-way 
ANOVA (B and D) and Two-way ANOVA (A) was used to compare the groups. * p < 0.05, ** P 
< 0.01 
Supplementary Figure 4: Acetate shifts gene-expression towards an immunomodulatory 
phenotype, related to figure 4. A) LmOVA-immunized mice were i.p. re-infected with 105 
CFU LmOVA in presence (blue) or absence (black) of 10 mM acetate. IL-10 was measured in 
the peritoneal fluid by cytometric bead array. B) Heatmap of the PCR-Array from peritoneal 
tissue of the mice described in (A). Red indicates increased, green decreased gene-
expression. Data was analyzed using the Qiagen RT2 Profiler Analysis Software. 
Each dot represents one mouse, lines indicate means, error bars are SD. Dashed lines
indicate the detection limit. T-test was used to compare the groups (A). 
